Heart failure therapies: new strategies for old treatments and new treatments for old strategies

Cardiovascular Pathology

Volumn 25, Issue 6, 2016, Pages 503-511

  Halushka, Marc K ^a   Mitchell, Richard N ^b   Padera, Robert F ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibody mediated rejection; Cellular rejection; Heart failure; Orthotopic heart transplantation; Ventricular assist device

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

CELL FREE SYSTEM; GENE EXPRESSION PROFILING; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSURVEILLANCE; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DEVICE COMPLICATION; PRIORITY JOURNAL; REVIEW; TOTAL ARTIFICIAL HEART; VASCULAR DISEASE; CARDIOLOGY; PROCEDURES; TRENDS;

CARDIOLOGY; HEART FAILURE; HUMANS;

EID: 84986612932     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2016.08.008     Document Type: Review

References (79)

1. [1] Writing Group M, Mozaffarian, D, Benjamin, EJ, Go, AS, Arnett, DK, Blaha, MJ, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e60.
2. [2] Long, EF, Swain, GW, Mangi, AA, Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 7 (2014), 470–478.
3. [3] Sutcliffe, P, Connock, M, Pulikottil-Jacob, R, Kandala, NB, Suri, G, Gurung, T, et al. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model. Health Technol Assess 17 (2013), 1–499 [v-vi].
4. [4] DeVries, WC, Anderson, JL, Joyce, LD, Anderson, FL, Hammond, EH, Jarvik, RK, et al. Clinical use of the total artificial heart. N Engl J Med 310 (1984), 273–278.
5. [5] Griffith, BP, Hardesty, RL, Kormos, RL, Trento, A, Borovetz, HS, Thompson, ME, et al. Temporary use of the Jarvik-7 total artificial heart before transplantation. N Engl J Med 316 (1987), 130–134.
6. [6] Saffarzadeh, A, Bonde, P, Options for temporary mechanical circulatory support. J Thorac Dis 7 (2015), 2102–2111.
7. [7] Rose, EA, Gelijns, AC, Moskowitz, AJ, Heitjan, DF, Stevenson, LW, Dembitsky, W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001), 1435–1443.
8. [8] Dagenais, F, Portner, PM, Robbins, RC, Oyer, PE, The Novacor left ventricular assist system: clinical experience from the Novacor registry. J Card Surg 16 (2001), 267–271.
9. [9] Farrar, DJ, Lawson, JH, Litwak, P, Cederwall, G, Thoratec VAD system as a bridge to heart transplantation. J Heart Transplant 9 (1990), 415–422 [discussion 22-3].
10. [10] Slaughter, MS, Rogers, JG, Milano, CA, Russell, SD, Conte, JV, Feldman, D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361 (2009), 2241–2251.
11. [11] Schmid, C, Tjan, TD, Etz, C, Schmidt, C, Wenzelburger, F, Wilhelm, M, et al. First clinical experience with the Incor left ventricular assist device. J Heart Lung Transplant 24 (2005), 1188–1194.
12. [12] Sorensen, EN, Pierson, RN, Feller, ED, Griffith, BP, University of Maryland surgical experience with the Jarvik 2000 axial flow ventricular assist device. Ann Thorac Surg 93 (2012), 133–140.
13. [13] Aaronson, KD, Slaughter, MS, Miller, LW, McGee, EC, Cotts, WG, Acker, MA, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 125 (2012), 3191–3200.
14. [14] Schmitto, JD, Hanke, JS, Rojas, SV, Avsar, M, Haverich, A, First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Heart Lung Transplant 34 (2015), 858–860.
15. [15] Saito, S, Yamazaki, K, Nishinaka, T, Ichihara, Y, Ono, M, Kyo, S, et al. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS. J Heart Lung Transplant 33 (2014), 599–608.
16. [16] Copeland, JG, Smith, RG, Arabia, FA, Nolan, PE, Sethi, GK, Tsau, PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 351 (2004), 859–867.
17. [17] Kirklin, JK, Naftel, DC, Pagani, FD, Kormos, RL, Myers, S, Acker, MA, et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS registry. J Heart Lung Transplant 34 (2015), 1515–1526.
18. [18] Morgan, JA, Go, PH, Xuereb, L, Kaur, B, Akrawe, S, Nemeh, HW, et al. Outcomes on continuous flow left ventricular assist devices: a single institutional 9-year experience. Ann Thorac Surg, 2016.
19. [19] Jorde, UP, Kushwaha, SS, Tatooles, AJ, Naka, Y, Bhat, G, Long, JW, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63 (2014), 1751–1757.
20. [20] Padera, RF, Infection in ventricular assist devices: the role of biofilm. Cardiovasc Pathol 15 (2006), 264–270.
21. [21] Mudd, JO, Cuda, JD, Halushka, M, Soderlund, KA, Conte, JV, Russell, SD, Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. J Heart Lung Transplant 27 (2008), 1269–1274.
22. [22] Shankar, N, Daly, R, Geske, J, Kushwaha, SK, Timmons, M, Joyce, L, et al. LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay. Transplantation 96 (2013), 324–330.
23. [23] John, R, Lietz, K, Schuster, M, Naka, Y, Rao, V, Mancini, DM, et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg 125 (2003), 578–591.
24. [24] Pagani, FD, Dyke, DB, Wright, S, Cody, R, Aaronson, KD, Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 20 (2001), 646–653.
25. [25] Ko, BS, Drakos, S, Kfoury, AG, Hurst, D, Stoddard, GJ, Willis, CA, et al. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. J Heart Lung Transplant, 2016.
26. [26] Kirklin, JK, Naftel, DC, Pagani, FD, Kormos, RL, Stevenson, LW, Blume, ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34 (2015), 1495–1504.
27. [27] Stewart, GC, Stevenson, LW, INTERMACS and MedaMACS: how will they guide future therapy?. Curr Cardiol Rep, 15, 2013, 394.
28. [28] Frazier, OH, Baldwin, AC, Demirozu, ZT, Segura, AM, Hernandez, R, Taegtmeyer, H, et al. Ventricular reconditioning and pump explantation in patients supported by continuous-flow left ventricular assist devices. J Heart Lung Transplant 34 (2015), 766–772.
29. [29] Drakos, SG, Kfoury, AG, Selzman, CH, Verma, DR, Nanas, JN, Li, DY, et al. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol 26 (2011), 245–255.
30. [30] Yusen, RD, Edwards, LB, Kucheryavaya, AY, Benden, C, Dipchand, AI, Goldfarb, SB, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report—2015; focus theme: early graft failure. J Heart Lung Transplant 34 (2015), 1264–1277.
31. [31] Andrew, J, Macdonald, P, Latest developments in heart transplantation: a review. Clin Ther 37 (2015), 2234–2241.
32. [32] Soderlund, C, Radegran, G, Immunosuppressive therapies after heart transplantation—the balance between under- and over-immunosuppression. Transplant Rev 29 (2015), 181–189.
33. [33] Kilic, A, Conte, JV, Shah, AS, Yuh, DD, Orthotopic heart transplantation in patients with metabolic risk factors. Ann Thorac Surg 93 (2012), 718–724.
34. [34] Alam, A, Badovinac, K, Ivis, F, Trpeski, L, Cantarovich, M, The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 7 (2007), 461–465.
35. [35] DePasquale, EC, Schweiger, M, Ross, HJ, A contemporary review of adult heart transplantation: 2012 to 2013. J Heart Lung Transplant 33 (2014), 775–784.
36. [36] Zafar, SY, Howell, DN, Gockerman, JP, Malignancy after solid organ transplantation: an overview. Oncologist 13 (2008), 769–778.
37. [37] Mitchell, RN, Graft vascular disease: immune response meets the vessel wall. Annu Rev Pathol 4 (2009), 19–47.
38. [38] Mehra, MR, Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 6 (2006), 1248–1256.
39. [39] Winters, GL, Schoen, FJ, Graft arteriosclerosis-induced myocardial pathology in heart transplant recipients: predictive value of endomyocardial biopsy. J Heart Lung Transplant 16 (1997), 985–993.
40. [40] Kobashigawa, JA, The future of heart transplantation. Am J Transplant 12 (2012), 2875–2891.
41. [41] Kobashigawa, JA, Moriguchi, JD, Laks, H, Wener, L, Hage, A, Hamilton, MA, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005), 1736–1740.
42. [42] van den Hoogen, P, Huibers, MM, Sluijter, JP, de Weger, RA, Cardiac allograft vasculopathy: a donor or recipient induced pathology?. J Cardiovasc Transl Res 8 (2015), 106–116.
43. [43] Caforio, AL, Tona, F, Fortina, AB, Angelini, A, Piaserico, S, Gambino, A, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 4 (2004), 962–970.
44. [44] Loupy, A, Toquet, C, Rouvier, P, Beuscart, T, Bories, MC, Varnous, S, et al. Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection. Am J Transplant 16 (2016), 111–120.
45. [45] Rose, ML, De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system. J Heart Lung Transplant 23 (2004), 385–395.
46. [46] Sis, B, Mengel, M, Haas, M, Colvin, RB, Halloran, PF, Racusen, LC, et al. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10 (2010), 464–471.
47. [47] Colvin, RB, Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 18 (2007), 1046–1056.
48. [48] Bates, RL, Frampton, G, Rose, ML, Murphy, JJ, High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease. Transplantation 75 (2003), 1347–1350.
49. [49] Reinsmoen, NL, Lai, CH, Mirocha, J, Cao, K, Ong, G, Naim, M, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 97 (2014), 595–601.
50. [50] Mengel, M, Husain, S, Hidalgo, L, Sis, B, Phenotypes of antibody-mediated rejection in organ transplants. Transpl Int 25 (2012), 611–622.
51. [51] Gill, J, Shah, T, Hristea, I, Chavalitdhamrong, D, Anastasi, B, Takemoto, SK, et al. Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data. Am J Transplant 9 (2009), 844–852.
52. [52] Guihaire, J, Mercier, O, Flecher, E, Aymami, M, Fattal, S, Chabanne, C, et al. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study. J Heart Lung Transplant 33 (2014), 636–643.
53. [53] Caves, PK, Stinson, EB, Billingham, ME, Rider, AK, Shumway, NE, Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J Thorac Cardiovasc Surg 66 (1973), 461–466.
54. [54] McAllister, HA, Histologic grading of cardiac allograft rejection: a quantitative approach. J Heart Transplant 9 (1990), 277–282.
55. [55] Billingham, ME, Cary, NR, Hammond, ME, Kemnitz, J, Marboe, C, McCallister, HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9 (1990), 587–593.
56. [56] Stewart, S, Winters, GL, Fishbein, MC, Tazelaar, HD, Kobashigawa, J, Abrams, J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005), 1710–1720.
57. [57] Berry, GJ, Burke, MM, Andersen, C, Bruneval, P, Fedrigo, M, Fishbein, MC, et al. The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 32 (2013), 1147–1162.
58. [58] Baraldi-Junkins, C, Levin, HR, Kasper, EK, Rayburn, BK, Herskowitz, A, Baughman, KL, Complications of endomyocardial biopsy in heart transplant patients. J Heart Lung Transplant 12 (1993), 63–67.
59. [59] Stehlik, J, Starling, RC, Movsesian, MA, Fang, JC, Brown, RN, Hess, ML, et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant 25 (2006), 1402–1409.
60. [60] Orrego, CM, Cordero-Reyes, AM, Estep, JD, Loebe, M, Torre-Amione, G, Usefulness of routine surveillance endomyocardial biopsy 6 months after heart transplantation. J Heart Lung Transplant 31 (2012), 845–849.
61. [61] McMinn, JF, Lang, NN, McPhadden, A, Payne, JR, Petrie, MC, Gardner, RS, Biomarkers of acute rejection following cardiac transplantation. Biomark Med 8 (2014), 815–832.
62. [62] Troughton, RW, Frampton, CM, Yandle, TG, Espiner, EA, Nicholls, MG, Richards, AM, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000), 1126–1130.
63. [63] Masters, RG, Davies, RA, Veinot, JP, Hendry, PJ, Smith, SJ, de Bold, AJ, Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 100 (1999), 287–291.
64. [64] Kittleson, MM, Skojec, DV, Wittstein, IS, Champion, HC, Judge, DP, Barouch, LA, et al. The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. The Journal of Heart and Lung Transplantation: the official publication of the International Society for Heart. Transplantation 28 (2009), 704–709.
65. [65] Damodaran, A, Dardas, T, Wu, AH, Dyke, DB, Hummel, SL, Cowger, JA, et al. Changes in serial B-type natriuretic peptide level independently predict cardiac allograft rejection. J Heart Lung Transplant 31 (2012), 708–714.
66. [66] Deng, MC, Eisen, HJ, Mehra, MR, Billingham, M, Marboe, CC, Berry, G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6 (2006), 150–160.
67. [67] Lin, D, Hollander, Z, Ng, RT, Imai, C, Ignaszewski, A, Balshaw, R, et al. Whole blood genomic biomarkers of acute cardiac allograft rejection. J Heart Lung Transplant 28 (2009), 927–935.
68. [68] Pham, MX, Teuteberg, JJ, Kfoury, AG, Starling, RC, Deng, MC, Cappola, TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 362 (2010), 1890–1900.
69. [69] De Vlaminck, I, Valantine, HA, Snyder, TM, Strehl, C, Cohen, G, Luikart, H, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med, 6, 2014, 241ra77.
70. [70] Hammond, EH, Yowell, RL, Nunoda, S, Menlove, RL, Renlund, DG, Bristow, MR, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 8 (1989), 430–443.
71. [71] Hammond, ME, Stehlik, J, Snow, G, Renlund, DG, Seaman, J, Dabbas, B, et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant 24 (2005), 2015–2021.
72. [72] Kfoury, AG, Hammond, ME, Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 29 (2010), 389–394.
73. [73] Kucirka, LM, Maleszewski, JJ, Segev, DL, Halushka, MK, Survey of North American pathologist practices regarding antibody-mediated rejection in cardiac transplant biopsies. Cardiovasc Pathol 20 (2011), 132–138.
74. [74] Kobashigawa, J, Crespo-Leiro, MG, Ensminger, SM, Reichenspurner, H, Angelini, A, Berry, G, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30 (2011), 252–269.
75. [75] Fedrigo, M, Feltrin, G, Poli, F, Frigo, AC, Benazzi, E, Gambino, A, et al. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant 32 (2013), 404–409.
76. [76] Fedrigo, M, Gambino, A, Benazzi, E, Poli, F, Frigo, AC, Tona, F, et al. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30 (2011), 1381–1388.
77. [77] Chih, S, Tinckam, KJ, Ross, HJ, A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant 13 (2013), 1069–1074.
78. [78] Frank, R, Dean, SA, Molina, MR, Kamoun, M, Lal, P, Correlations of lymphocyte subset infiltrates with donor-specific antibodies and acute antibody-mediated rejection in endomyocardial biopsies. Cardiovasc Pathol 24 (2015), 168–172.
79. [79] Fedrigo, M, Leone, O, Burke, MM, Rice, A, Toquet, C, Vernerey, D, et al. Inflammatory cell burden and phenotype in endomyocardial biopsies with antibody-mediated rejection (AMR): a multicenter pilot study from the AECVP. Am J Transplant 15 (2015), 526–534.